Experienced in Disseminated Intravascular Coagulation

Ying E. Yuan

No.639 Zhizaoju Road, 
Shanghai, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Disseminated Intravascular Coagulation
No.639 Zhizaoju Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Ying Yuan practices in Shanghai, China. Yuan is rated as an Experienced expert by MediFind in the treatment of Disseminated Intravascular Coagulation. Their top areas of expertise are Colorectal Cancer, Childhood Pancreatitis, Head and Neck Squamous Cell Carcinoma (HNSCC), Endoscopy, and Percutaneous Coronary Intervention (PCI).

Their clinical research consists of co-authoring 986 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Disseminated Intravascular Coagulation.

Locations

No.639 Zhizaoju Road, Shanghai, 200010, China
Other Locations
1111, Xianxia Road, Shanghai, 200336, China
99 Xuefu Road, Suzhou, 215009, China
79# Qingchun Road, Hangzhou, 310003, China
No. 11 Guangqian Road, Suzhou, 215137, China
No. 1200 Cailun Road, Pudong, 201203, China
305 East Zhongshan Road, Nanjing, 210002, China
No.639 Zhizaoju Road, Shanghai, China
218 Xinghu Street, Building B2, Suite 711, Suzhou Industrial Park, Suzhou, 215123, China
Rm 201, 899 Pinghai Road, Suzhou, 215031, China
No. 1200 Cailun Road, Pudong, China
88 Jiefang Road, Hangzhou, 310009, China
No. 88, Jiefang Road, Hangzhou, China
20 Xisi Road, Nantong, 226001, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Other
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Zanidatamab, Tislelizumab, Trastuzumab, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Study Phase: Phase 3
A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer
A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: April 04, 2024
Intervention Type: Drug, Other
Study Drugs: Nimotuzumab, Gemcitabine
Study Phase: Phase 3
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Enrollment Status: Completed
Publish Date: June 14, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

985 Total Publications

Correction to "Laser-Ultrasound Responsive Nanoreactor to Remodel the Microenvironment of Antibiotic-Resistant Bacterial Infection for Diabetic Wound Healing".
Correction to "Laser-Ultrasound Responsive Nanoreactor to Remodel the Microenvironment of Antibiotic-Resistant Bacterial Infection for Diabetic Wound Healing".
Journal: Nano letters
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yuan's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 127 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile